Author

Z. Ang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

A. Thomas-Tikhonenko· 2 shared C. D. Falkenstein· 2 shared K. E. Hayer· 2 shared M. M. Li· 2 shared S. K. Tasian· 2 shared Y. Barash· 2 shared A. Castro· 1 shared A. Ferrando· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Thomas-Tikhonenko

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

An Alternatively Spliced Gain-of-Function NT5C2 Isoform Contributes to Chemoresistance in Acute Lymphoblastic Leukemia

M. T. Diz, C. Reglero, C. D. Falkenstein, A. Castro, K. E. Hayer, C. Radens, M. Quesnel-Vallieres, Z. Ang, P. Sehgal, M. M. Li, Y. Barash, S. K. Tasian, A. Ferrando, A. Thomas-Tikhonenko

The paper identifies an alternatively spliced NT5C2 isoform contributing to chemoresistance in B-ALL by enhancing nucleosidase activity and 6-MP resistance.

bioRxiv · Sep 14, 2023Cancer Biology

Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies

Z. Ang, L. Paruzzo, K. E. Hayer, C. Schmidt, M. Torres Diz, F. Xu, U. Zankharia, Y. Zhang, S. Soldan, S. Zheng, C. D. Falkenstein, J. P. Loftus, S. Y. Yang, M. Asnani, P. King Sainos, , A. Thomas-Tikhonenko

This study identifies alternative splicing of CD20 mRNA that generates translation-deficient isoforms, contributing to resistance to CD20-directed immunotherapies.

bioRxiv · Feb 19, 2023Immunology